Select Publications

Preprints

Shih ST; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, 2022, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267510

Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, 2021, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916

Lockhart I; Yeo MGH; Hajarizadeh B; Dore GJ; Danta M, 2021, Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis, http://dx.doi.org/10.2139/ssrn.3950271

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, 2020, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, http://dx.doi.org/10.2139/ssrn.3709824

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2018, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607

McKetin R; Degan T; Saunders L; Nguyen L; Dore G; Shoptaw S; Farrell M; Degenhardt L; Kelly PJ; Turner A; Clare PJ; Dean OM; Arunogiri S; Colledge-Frisby S; Koeijers J; Goodman-Meza D; Sinclair B; Reid D; Hill H; Hayllar J; Christmass M; Cordaro F; Lundin R; Liaw W; Liu D; Holyoak E; Wu BT-F; Kegan J; Kontogiannis A; Palmer L; Morrison C; Wrobel A; Hyland R; Byrne M; Zahra E; Russell S; Berk M, A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: A study protocol for the Tina Trial, http://dx.doi.org/10.21203/rs.3.rs-3984655/v1

Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, http://dx.doi.org/10.2139/ssrn.3213670

Ramsay E; Stocks N; Bernando C; Nobre F; Stepien S; Gonzalez-Chica D; Prasad SA; Dore GJ; Macartney K; Wood J; Walsh D; Newall A; Cheng AC; Hogan AB; Bindra GK; Wilkins D; Liu B, Characteristics of post-acute COVID-19 presentations and healthcare use in Australian general practice and comparisons to those with acute COVID-19 and upper respiratory tract infection, http://dx.doi.org/10.21203/rs.3.rs-7561005/v1

Carson JM; Barbieri S; Verich A; Tu E; Lloyd A; Dore GJ; Matthews GV; Martinello M, Development of a machine learning model to predict short duration HCV treatment response, http://dx.doi.org/10.1101/2025.09.19.25336147

Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham EB; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran L; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J, Global, Regional, and Country-Level Coverage of Testing and Treatment for HIV and Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review, http://dx.doi.org/10.2139/ssrn.4402728

Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Group RS, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947

Phetsouphanh C; Darley D; Wilson DB; Howe A; Munier CML; Patel SK; Juno JA; Burrell LM; Kent SJ; Dore GJ; Kelleher AD; Matthews GV, Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection, http://dx.doi.org/10.1101/2021.06.01.21257759

Wu H-J; Grebely J; Applegate TL; Kwon JA; Cheng Q; Martinello M; Sheehan Y; Hajarizadeh B; Wiseman V; Cunningham EB; Dore GJ; Lloyd AR; Matthews S; Markus C; Marshall AD; Lafferty L; Kingsland M; Causer LM; Pedrana A; Fontaine G; Taylor N; Clynes L; Murray J; Shih ST; Gray RT; Hepatitis C Point-of-Care Testing Progrm A, Impact And Cost-Effectiveness Of Scaling Up A National Point-Of-Care Hepatitis C Testing And Treatment Program In Australia: A Mathematical Modelling Study, http://dx.doi.org/10.2139/ssrn.7445300

Phetsouphanh C; Jacka B; Ballouz S; Jackson KJ; Wilson DB; Manandhar B; Klemm V; Tan H-X; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville SG; Kent SJ; Byrne A; Brew BJ; Darley DR; Dore GJ; Kelleher AD; Matthews GV, Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection, http://dx.doi.org/10.1101/2023.08.27.23294704

Darley ; Dore G; Byrne A; Plit M; Brew B; Kelleher A; Matthews G, Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort, http://dx.doi.org/10.1101/2021.03.29.21254211

Shih ST; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon JA; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, http://dx.doi.org/10.2139/ssrn.4267527

Cysique LA; Jakabek D; Bracken SG; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Pires AS; Darley DR; Byrne A; Phetsouphanh C; Kelleher A; Dore GJ; Matthews GV; Guillemin GJ; Brew BJ, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study, http://dx.doi.org/10.1101/2022.06.07.22276020

Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffman M; Pöhlmann S; Dwyer DE; Rockett R; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants, http://dx.doi.org/10.1101/2020.12.19.20248567

Young C; Singh M; Jackson KJ; Field MA; Peters TJ; Angioletti-Uberti S; Frenkel D; Ravishankar S; Gupta M; Wang JJ; Agapiou D; Faulks ML; Al-Eryani G; Luciani F; Gordon TP; Reed JH; Danta M; Carr A; Kelleher AD; Dore GJ; Matthews G; Brink R; Bull RA; Suan D; Goodnow CC, Self-reactive B cells traverse a perfect storm of somatic mutagenesis to cause a virus-induced autoimmune disease, http://dx.doi.org/10.1101/2024.01.07.574561

Yeoh YKJ; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B, Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia, http://dx.doi.org/10.1101/2023.02.20.23286164

Joseph S; Dore GJ, Vaccine Apartheid: A Human Rights Analysis of COVID-19 Vaccine Inequity, http://dx.doi.org/10.2139/ssrn.3876848


Back to profile page